Selective blockade of Ca
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
21
04
2023
accepted:
10
11
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
L-type voltage-gated calcium channels are involved in multiple physiological functions. Currently available antagonists do not discriminate between L-type channel isoforms. Importantly, no selective blocker is available to dissect the role of L-type isoforms Ca
Identifiants
pubmed: 38167790
doi: 10.1038/s41467-023-43502-w
pii: 10.1038/s41467-023-43502-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54Subventions
Organisme : Fondation Leducq
ID : 19CV03
Organisme : Fondation Leducq
ID : 19CV03
Informations de copyright
© 2024. The Author(s).
Références
Zamponi, G. W., Striessnig, J., Koschak, A. & Dolphin, A. C. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Sibl. DR Pharm. Rev. Am. Soc. Pharmacol. Exp. Therapeut. 67, 821–870 (2015).
Catterall, W. A. Voltage-gated calcium channels. Cold Spring Harb Perspect Biol. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140680/ (2011).
Dolphin, A. C. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J. Physiol. 594, 5369–5390 (2016).
pubmed: 27273705
pmcid: 5043047
doi: 10.1113/JP272262
Bers, D. Ca channels in cardiac myocytes: structure and function in Ca influx and intracellular Ca release. Cardiovasc. Res. 42, 339–360 (1999).
pubmed: 10533572
doi: 10.1016/S0008-6363(99)00038-3
Marionneau, C. et al. Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart: Ion channel expression in the murine heart. J. Physiol. 562, 223–234 (2005).
pubmed: 15498808
doi: 10.1113/jphysiol.2004.074047
Bers, D. M. Cardiac excitation–contraction coupling. Nature 415, 198–205 (2002).
pubmed: 11805843
doi: 10.1038/415198a
Papa, A., Kushner, J. & Marx, S. O. Adrenergic regulation of calcium channels in the heart. Annu. Rev. Physiol. 84, 285–306 (2022).
pubmed: 34752709
doi: 10.1146/annurev-physiol-060121-041653
Mangoni, M. E. et al. Functional role of L-type Cav1.3 Ca2+ channels in cardiac pacemaker activity. Proc. Natl Acad. Sci. USA 100, 5543–5548 (2003).
pubmed: 12700358
pmcid: 154381
doi: 10.1073/pnas.0935295100
Mesirca, P. et al. G protein-gated IKACh channels as therapeutic targets for treatment of sick sinus syndrome and heart block. Proc. Natl Acad. Sci. USA 113, E932–E941 (2016).
pubmed: 26831068
pmcid: 4763776
doi: 10.1073/pnas.1517181113
Baudot, M. et al. Concomitant genetic ablation of L-type Cav1.3 (α1D) and T-type Cav3.1 (α1G) Ca2+ channels disrupts heart automaticity. Sci. Rep. 10, 18906 (2020).
pubmed: 33144668
pmcid: 7642305
doi: 10.1038/s41598-020-76049-7
Mangoni, M. E. & Nargeot, J. Genesis and regulation of the heart automaticity. Physiol. Rev. Am. Physiol. Soc. 88, 919–982 (2008).
Chicheportiche, R., Vincent, J.-P., Kopeyan, C., Schweitz, H. & Lazdunski, M. Structure-function relationship in the binding of snake neurotoxins to the torpedo membrane receptor? Biochemistry 14, 2081–2091 (1975).
pubmed: 1148159
doi: 10.1021/bi00681a007
Bourne, Y., Renault, L. & Marchot, P. Crystal structure of snake venom acetylcholinesterase in complex with inhibitory antibody fragment Fab410 bound at the peripheral site. J. Biol. Chem. 290, 1522–1535 (2015).
pubmed: 25411244
doi: 10.1074/jbc.M114.603902
Diochot, S. et al. Black mamba venom peptides target acid-sensing ion channels to abolish pain. Nature 490, 552–555 (2012).
pubmed: 23034652
doi: 10.1038/nature11494
Vincent, J. P. et al. Molecular mechanism of cardiotoxin action on axonal membranes. Biochemistry 15, 3171–3175 (1976).
pubmed: 182204
doi: 10.1021/bi00660a002
de Weille, J. R., Schweitz, H., Maes, P., Tartar, A. & Lazdunski, M. Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel. Proc. Natl Acad. Sci. USA 88, 2437–2440 (1991).
pubmed: 1848702
pmcid: 51247
doi: 10.1073/pnas.88.6.2437
Bock, G. et al. Functional properties of a newly identified C-terminal splice variant of Cav1.3 L-type Ca2+ channels. J. Biol. Chem. 286, 42736–42748 (2011).
pubmed: 21998310
pmcid: 3234942
doi: 10.1074/jbc.M111.269951
Singh, A. et al. Modulation of voltage- and Ca2+-dependent gating of CaV1.3 L-type calcium channels by alternative splicing of a C-terminal regulatory domain. J. Biol. Chem. 283, 20733–20744 (2008).
pubmed: 18482979
pmcid: 2475692
doi: 10.1074/jbc.M802254200
Chouabe, C., Drici, M.-D., Romey, G., Barhanin, J. & Lazdunski, M. HERG and KvLQT1/IsK, the Cardiac Kϩ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol. Pharmacol. 54, 695–703 (1998).
pubmed: 9765513
Hockerman, G. H., Peterson, B. Z., Johnson, B. D. & Catterall, W. A. Molecular determinants of drug binding and action on l-type calcium channels. Annu. Rev. Pharm. Toxicol. 37, 361–396 (1997).
doi: 10.1146/annurev.pharmtox.37.1.361
Moosmang, S., Lenhardt, P., Haider, N., Hofmann, F. & Wegener, J. W. Mouse models to study L-type calcium channel function. Pharmacol. Therapeut. 106, 347–355 (2005).
doi: 10.1016/j.pharmthera.2004.12.003
Shah, K., Seeley, S., Schulz, C., Fisher, J. & Gururaja Rao, S. Calcium channels in the heart: disease states and drugs. Cells 11, 943 (2022).
pubmed: 35326393
pmcid: 8945986
doi: 10.3390/cells11060943
Splawski, I. et al. CaV1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19–31 (2004).
pubmed: 15454078
doi: 10.1016/j.cell.2004.09.011
Striessnig, J. Pharmacology, structure and function of cardiac L-Type Ca
pubmed: 10575201
doi: 10.1159/000016320
Eisenberg, M. J., Brox, A. & Bestawros, A. N. Calcium channel blockers: an update. Am. J. Med. 116, 35–43 (2004).
pubmed: 14706664
doi: 10.1016/j.amjmed.2003.08.027
Striessnig, J., Ortner, N. & Pinggera, A. Pharmacology of L-type calcium channels: novel drugs for old targets? CMP 8, 110–122 (2015).
doi: 10.2174/1874467208666150507105845
Triggle, D. J. 1,4-Dihydropyridines as calcium channel ligands and privileged structures. Cell. Mol. Neurobiol. 23, 293–303 (2003).
pubmed: 12825828
doi: 10.1023/A:1023632419813
de Vries, R. J. M., van Veldhuisen, D. J. & Dunselman, P. H. J. M. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. Am. Heart J. 139, 185–194 (2000).
pubmed: 10650289
doi: 10.1016/S0002-8703(00)90224-2
Epstein, M. Calcium antagonists: still appropriate as first line antihypertensive agents. Am. J. Hypertens. 9, 110–121 (1996).
pubmed: 8924260
doi: 10.1016/0895-7061(96)00013-1
Chang, C.-C. et al. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels CaV1.3 and CaV1.2. Bioorg. Med. Chem. 18, 3147–3158 (2010).
pubmed: 20382537
doi: 10.1016/j.bmc.2010.03.038
Qar, J. et al. A novel high affinity class of Ca2+ channel blockers. Mol. Pharm. Am. Soc. Pharmacol. Exp. Therapeut. 33, 363–369 (1988).
Schmid, A., Romey, G., Barhanin, J. & Lazdunski, M. SR33557, an indolizinsulfone blocker of Ca2+ channels: identification of receptor sites and analysis of its mode of action. Mol. Pharm. Am. Soc. Pharmacol. Exp. Therapeut. 35, 766–773 (1989).
Triggle, D. L-type calcium channels. CPD 12, 443–457 (2006).
doi: 10.2174/138161206775474503
Narahashi, T., Moore, J. W. & Scott, W. R. Tetrodotoxin blockage of sodium conductance increase in lobster giant axons. J. Gen. Physiol. 47, 965–974 (1964).
pubmed: 14155438
pmcid: 2195365
doi: 10.1085/jgp.47.5.965
Hugues, M., Romey, G., Duval, D., Vincent, J. P. & Lazdunski, M. Apamin as a selective blocker of the calcium-dependent potassium channel in neuroblastoma cells: voltage-clamp and biochemical characterization of the toxin receptor. Proc. Natl Acad. Sci. USA 79, 1308–1312 (1982).
pubmed: 6122211
pmcid: 345952
doi: 10.1073/pnas.79.4.1308
McCleskey, E. W. et al. Omega-conotoxin: direct and persistent blockade of specific types of calcium channels in neurons but not muscle. Proc. Natl Acad. Sci. USA 84, 4327–4331 (1987).
pubmed: 2438698
pmcid: 305078
doi: 10.1073/pnas.84.12.4327
Escoubas, P. et al. Isolation of a tarantula toxin specific for a class of proton-gated Na+ channels. J. Biol. Chem. 275, 25116–25121 (2000).
pubmed: 10829030
doi: 10.1074/jbc.M003643200
Matthes, J. et al. Disturbed atrio-ventricular conduction and normal contractile function in isolated hearts from Ca v 1.3-knockout mice. Naun. Schmiedeberg. Arch. Pharmacol. 369, 554–562 (2004).
doi: 10.1007/s00210-004-0940-7
Klugbauer, N., Welling, A., Specht, V., Seisenberger, C. & Hofmann, F. L-type Ca2+ channels of the embryonic mouse heart. Eur. J. Pharmacol. 447, 279–284 (2002).
pubmed: 12151019
doi: 10.1016/S0014-2999(02)01850-2
Mesirca, P., Torrente, A. G. & Mangoni, M. E. Functional role of voltage gated Ca(2+) channels in heart automaticity. Front Physiol. 6, 19 (2015).
pubmed: 25698974
pmcid: 4313592
doi: 10.3389/fphys.2015.00019
Seisenberger, C. et al. Functional embryonic cardiomyocytes after disruption of the L-type α1C (Ca 1.2) calcium channel gene in the mouse. J. Biol. Chem. 275, 39193–39199 (2000).
pubmed: 10973973
doi: 10.1074/jbc.M006467200
Rosati, B. et al. Robust L-type calcium current expression following heterozygous knockout of the Cav1.2 gene in adult mouse heart: Robust expression of L-type calcium current. J. Physiol. 589, 3275–3288 (2011).
pubmed: 21521762
pmcid: 3145939
doi: 10.1113/jphysiol.2011.210237
Moosmang, S. et al. Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation. EMBO J. John Wiley Sons Ltd. 22, 6027–6034 (2003).
Teramoto, N. et al. Effects of calciseptine on unitary barium channel currents in guinea-pig portal vein. Pflug. Arch. Eur. J. Physiol. 432, 462–470 (1996).
doi: 10.1007/s004240050158
Yasuda, O. et al. Calciseptine binding to a 1,4-dihydropyridine recognition site of the L-type calcium channel of rat synaptosomal membranes. Biochem. Biophys. Res. Commun. 194, 587–594 (1993).
pubmed: 8393668
doi: 10.1006/bbrc.1993.1862
Sinnegger-Brauns, M. J. et al. Isoform-specific regulation of mood behavior and pancreatic β cell and cardiovascular function by L-type Ca2+ channels. J. Clin. Invest. 113, 1430–1439 (2004).
pubmed: 15146240
pmcid: 406526
doi: 10.1172/JCI20208
McDonough, S. I., Boland, L. M., Mintz, I. M. & Bean, B. P. Interactions among toxins that inhibit N-type and P-type calcium channels. J. Gen. Physiol. 119, 313–328 (2002).
pubmed: 11929883
pmcid: 2311392
doi: 10.1085/jgp.20028560
Watanabe, T. X. et al. Smooth muscle relaxing and hypotensive activities of synthetic calciseptine and the homologous snake venom peptide FS2. Jpn. J. Pharmacol. 68, 305–315 (1995).
pubmed: 7474554
doi: 10.1254/jjp.68.305
Kini, R. M. et al. Flanking proline residues identify the L-Type Ca
pubmed: 9636051
doi: 10.1021/bi9802723
Striessnig, J., Pinggera, A., Kaur, G., Bock, G. & Tuluc, P. L-type Ca2+ channels in heart and brain. Wiley Interdiscip. Rev. Membr. Transp. Signal 3, 15–38 (2014).
pubmed: 24683526
pmcid: 3968275
doi: 10.1002/wmts.102
Lacinova, L., Moosmang, S., Langwieser, N., Hofmann, F. & Kleppisch, T. Cav1.2 calcium channels modulate the spiking pattern of hippocampal pyramidal cells. Life Sci. 82, 41–49 (2008).
pubmed: 18045623
doi: 10.1016/j.lfs.2007.10.009
Moosmang, S. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J. Neurosci. 25, 9883–9892 (2005).
pubmed: 16251435
pmcid: 6725564
doi: 10.1523/JNEUROSCI.1531-05.2005
Santiago González, D. A. et al. Conditional deletion of the L-type calcium channel Cav1.2 in NG2-positive cells impairs remyelination in mice. J. Neurosci. 37, 10038–10051 (2017).
pubmed: 28899915
pmcid: 5647766
doi: 10.1523/JNEUROSCI.1787-17.2017
Zampese, E. et al. Ca
pubmed: 36179023
pmcid: 9524841
doi: 10.1126/sciadv.abp8701
Guzman, J. N. et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696–700 (2010).
pubmed: 21068725
pmcid: 4465557
doi: 10.1038/nature09536
Filippini, L., Ortner, N. J., Kaserer, T. & Striessnig, J. Cav1.3‐selective inhibitors of voltage‐gated L‐type Ca
pubmed: 36788128
doi: 10.1111/bph.16060
Kang, S. et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson’s disease. Nat. Commun. 3, 1146 (2012).
pubmed: 23093183
doi: 10.1038/ncomms2149
Huang, H. et al. Modest CaV1.342-selective inhibition by compound 8 is β-subunit dependent. Nat. Commun. 5, 4481 (2014).
pubmed: 25057870
doi: 10.1038/ncomms5481
Ortner, N. J. et al. Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+ channel activators. Nat. Commun. 5, 3897 (2014).
pubmed: 24941892
doi: 10.1038/ncomms4897
Catalucci, D. et al. Akt regulates L-type Ca2+ channel activity by modulating Cavα1 protein stability. J. Cell Biol. 184, 923–933 (2009).
pubmed: 19307602
pmcid: 2699149
doi: 10.1083/jcb.200805063